Drug Repurposing for Metabolic-Associated Fatty Liver Disease: Current Evidence, Challenges, and Future Perspectives Authors: Xiaonan Liang, Ping Jin, Yan Xue, Yongliang Jia, Hongmei Zhu, Guiyi Gong, Hua Zhou, Hao Hu, Simon Ming-Yuen Lee Published: 2026 ABSTRACT AbstractMetabolic dysfunction-associated fatty liver disease (MAFLD) is a prevalent chronic liver condition with limited approved pharmacotherapies. Drug repurposing offers a time-efficient alternative to de novo development, yet existing reviews often compile candidate compounds without critically appraising the methodological robustness, evidence quality, or translational barriers. In this review, we evaluated current repurposing strategies, including real-world data analyses, computational screening, and experimental validations. As a preliminary search for this review, we searched PubMed and clinical trial registries up to October 2025 using predefined search terms related to MAFLD, drug repurposing, and clinical trials. Despite numerous computational predictions and preclinical candidates, only a small fraction have advanced to late-stage trials. To date, regulatory approvals for MAFLD remain limited, with only a few agents approved and even fewer through repurposing. We examine key obstacles to clinical success, including patient heterogeneity, lack of validated biomarkers, inconsistent endpoint selection, and limited mechanistic target validation. In addition, we discuss the integration of multi-omics and AI-driven approaches with phenotypic screening as a promising avenue for target identification and validation. Our findings suggest that successful repurposing in MAFLD may benefit from a shift toward evidence-based, mechanism-informed frameworks, supported by real-world evidence and adaptive trial designs. This review summarizes current evidence and identifies open questions that may guide future research and clinical development. Introduction Metabolic-associated fatty liver disease (MAFLD), formerly termed non-alcoholic fatty liver disease (NAFLD), has emerged as a preeminent global health challenge, affecting an estimated 25% of the adult worldwide population.1 Characterized by hepatic steatosis in the absence of excessive alcohol intake, this disorder is now recognized as a hepatic manifestation of systemic metabolic derangement.2 The MAFLD spectrum spans from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), with potential progression to advanced liver pathologies including cirrhosis, liver failure and hepatocellular carcinoma (HCC).3 Closely intertwined with metabolic syndrome, obesity, insulin resistance and type 2 diabetes mellitus (T2DM), MAFLD underscores its role as a cardinal feature of systemic metabolic dyshomeostasis.4 Developing effective MAFLD therapeutics presents multiple challenges for many reasons: the complexity of interconnected pathophysiology of MAFLD, significant interpatient heterogeneity, as well as stringent therapeutic endpoints requiring simultaneous hepatic histological improvement, biochemical marker normalization, and clinically meaningful benefits.5 Current MAFLD/MASH drug development mainly focuses on emerging therapeutic targets addressing the key mechanisms of disease pathogenesis. Investigational drugs (IND) include peroxisome proliferator-activated receptor (PPAR) agonists,6 fibroblast growth factor (FGF) analogs,7 thyroid hormone receptor beta (THR-β) agonists, and farnesoid X receptor (FXR) agonists,8,9 etc. Details about these drug candidates are summarized in Table 1. While progress has been made in recent years, overall advancement remains uneven, and candidates demonstrating sufficient efficacy remain limited.10 Several IND drugs were terminated or failed in different clinical trial phases. For example, the ASK1 inhibitor selonsertib failed in a Phase III clinical trial (NCT03053063) for MASH patients with bridging fibrosis.11 The Phase II clinical trial for FXR agonist tropifexor (NCT02855164) was terminated.9 And the cysteine–cysteine (C-C) motif chemokine receptor 2 or chemokine receptor 5 (CCR2/CCR5) inhibitor cenicriviroc failed in Phase III clinical trials.12 These unsuccessful cases have led to a recent surge in failure rates in screening failure rates,13 which elongates development timelines and worsens the dearth of therapies ready for use.14 The US Food and Drug Administration (FDA) has currently approved only two drugs for MAFLD: one is resmetirom, which is indicated for MASH patients with significant liver fibrosis, and the other one is semaglutide targeting non-cirrhotic MASH patients with moderate-to-severe fibrosis.Table 1Representative Clinical Trials of Drug Development Candidates for MAFLD/MASH Included in This ReviewTarget/Drug ClassDrugPopulation/PatientsPhases of Clinical TrialsNCT Number (Reference)Trial PeriodCurrent StatusKey Findings/ConclusionPPAR agonistsLanifibranor (IVA-337)MASHPhase IINCT030080702017-2020CompletedThe percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher among those who received the 1200-mg dose, but not among those who received the 800-mg dose, of lanifibranor than among those who received placebo (1200-mg dose vs placebo, 55% vs 33%, P = 0.007; 800-mg dose vs placebo, 48% vs 33%, P = 0.07).T2DM and MAFLDPhase IINCT034590792018–2023CompletedLanifibranor significantly lowered IHTG compared to placebo (full analysis set [FAS] −44% vs −12%, respectively; least squares mean difference −31%, 95% CI −51 to −12%; in completers −50% vs −16%; both p <0.01).MASHPhase IIINCT048497282021-2026Ongoing-FGF19 analoguesAldafermin (NGM282)MASHPhase IINCT024431162015-2020CompletedAt week 24, the aldafermin group had a significant reduction in absolute liver fat content (reduction of 7.7%) compared with placebo (reduction of 2.7%; difference, reduction of 5.0%; 95% confidence interval, reduction of 8.0%-1.9%; P =0.002).FGF1R agonistsFazpilodemab (BFKB8488A)MAFLD and T2MDPhase INCT030605382017-2019CompletedBFKB8488A exhibited nonlinear pharmacokinetics, with greater than dose-proportional increases in exposure. The treatment-emergent antidrug antibody incidence was 22.7%.FGF21 analoguesPegozaferminMASHPhase IINCT049294832021-2024CompletedThe percentage of patients who met the criteria for NASH resolution was 2% in the placebo group, 37% in the 15-mg pegozafermin group (difference vs placebo, 35 percentage points; 95% CI, 10 to 59), 23% in the 30-mg pegozafermin group (difference, 21 percentage points; 95% CI, 9 to 33), and 26% in the 44-mg pegozafermin group (difference, 24 percentage points; 95% CI, 10 to 37).PegbelferminMASHPhase IINCT024133722015-2017CompletedThere is a significant decrease in absolute hepatic fat fraction in the group receiving 10 mg pegbelfermin daily (−6·8% vs −1·3%; p=0·0004) and in the group receiving 20 mg pegbelfermin weekly (−5·2% vs −1·3%; p=0·008) compared with the placebo group.Efruxifermin (EFX)MASHPhase IIINCT062157162023-2032Ongoing-SCD1 inhibitorsAramchol free acidMASHPhase IIINCT041043212019-2027SuspendedInterim analysis results from the open-label part of the study. The double blind portion of the study will be resumed once the study will continue.ASK1 inhibitorsSelonsertib (GS-4997)MASHPhase IIINCT030530502017-2019TerminatedThis study was terminated early due to lack of efficacy based on the results of the Week 48 analysis as prespecified in the clinical study protocol.MASHPhase IIINCT030530632017-2019TerminatedThis study was terminated early due to lack of efficacy based on the results of the Week 48 analysis as prespecified in the clinical study protocol.FASN inhibitorsDenifanstat (TVB-2640)MASHPhase IINCT039382462019-2021CompletedLiver fat increased in the placebo cohort by 4.5% relative to baseline; in contrast TVB-2640 reduced liver fat by 9.6% in the 25-mg cohort (n = 30; least squares mean: −15.5%; 95% confidence interval, −31.3 to −0.23; P =0.053), and 28.1% in the 50-mg cohort (n = 28; least squares mean: −28.0%; 95% confidence interval, −44.5 to −11.6; P =0.001).MPC inhibitorsMSDC-0602KMASHPhase IINCT027844442016-2019CompletedThe primary endpoint was reached in 29.7%, 29.8%, 32.9% and 39.5% of patients in the placebo, 62.5 mg, 125 mg and 250 mg dose arms, respectively, with adjusted odds ratios relative to placebo of 0.89 (95% CI 0.44–1.81), 1.22 (95% CI 0.60–2.48), and 1.64 (95% CI 0.83–3.27). The 2 highest doses of MSDC-0602K led to significant reductions in glucose, glycated hemoglobin, insulin, liver enzymes and NAS compared to placebo. AMPK activatorsPXL770MAFLDPhase IINCT037638772019-2020CompletedThe mean relative change from baseline in liver fat content at week 12 was −1·1% in the placebo group, −1·0% in the 250 mg once daily group (mean difference versus placebo 0·1% [95% CI −15·4 to 15·7], p=0·99), −14·3% in the 250 mg twice daily group (−13·1% [−28·1 to 1·8], p=0·084), and −14·7% in the 500 mg once daily group (−13·5% [−28·5 to 1·4], p=0·076).Oltipraz(RP 35972)MAFLD except liver cirrhosisPhase IIINCT041427492019-2022CompletedNo Study Results Posted on ClinicalTrials.gov for this StudyCCR2/5 inhibitorsCenicrivirocMASHPhase IIINCT030287402017-2021TerminatedThis study was terminated early due to lack of efficacy based on the results of the planned interim analysis of Part 1 data.AOC3 inhibitorBI 1467335MASHPhase IINCT031667352017-2019CompletedMean AOC3 activities relative to baseline at Week 12: 90.4% (placebo; n = 32), 26.5% (1 mg; n = 16), 10.4% (3 mg; n = 16), 5.0% (6 mg; n = 16), 3.3% (10 mg; n = 32). These changes indicated that BI 1467335 dose-dependently inhibited AOC3 activity; ≥3 mg doses achieved >80% inhibition (< 20% activity) at Week 4.Pan-PDE inhibitorZSP1601MASHPhase I/IINCT041401232020-2021CompletedThe primary outcomes were the safety and tolerability of ZSP1601. A total of 27 (27/36, 75%) patients experienced at least one treatment-emergent adverse event (TEAE). Most TEAEs were mild to moderate. There was no Serious Adverse Event. Diarrhea, transiently elevated creatinine and adaptive headache were frequently reported adverse drug reaction.FXR agonistsTropifexor (LJN452)MASHPhase IINCT028551642016-2020TerminatedDecreases from baseline in ALT and HFF were greater with tropifexor versus placebo at week 12, with a relative decrease in least squares mean from baseline observed with all tropifexor doses for ALT (tropifexor 10–90-μg dose groups ranged from −10.7 to −16.5 U l−1 versus placebo (−7.8 U l−1) and tropifexor 140- and 200-μg groups were −18.0 U l−1 and −23.0 U l−1, respectively, versus placebo (−8.3 U l−1)) and % HFF (tropifexor 10–90-μg dose groups ranged from −7.48% to −15.04% versus placebo (−6.19%) and tropifexor 140- and 200-μg groups were −19.07% and −39.41%, respectively, versus placebo (−10.77%)). Decreases in ALT and HFF were sustained up to week 48; however, similar trends in AST with tropifexor at week 12 were not observed. As with other FXR agonists, dose-related pruritus was frequently observed.EDP-305MASHPhase IINCT043780102020-2021TerminatedEnanta Pharmaceuticals, Inc. made the strategic decision to discontinue the ARGON-2 study to prioritize combination treatment approaches. This decision was not based on safety concerns.GLP1R/GCGR/GIPR agonistsEfinopegdutide (MK-6024)MAFLDPhase IINCT049449922021-2022CompletedThe least squares (LS) mean relative reduction from baseline in LFC at Week 24 was significantly (p <0.001) greater with efinopegdutide (72.7% [90% CI 66.8–78.7]) than with semaglutide (42.3% [90% CI 36.5–48.1]). Both treatment groups had an LS mean percent reduction from baseline in body weight at Week 24 (efinopegdutide 8.5% vs semaglutide 7.1%; p = 0.085).HSD17B13 inhibitorsARO-HSD (GSK4532990)MASHPhase IINCT055833442023-2026Ongoing-INI-822MASHPhase INCT059455372023-2025Ongoing-DGAT1/2 inhibitorsErvogastat (PF-06865571)MAFLDPhase INCT035135882018-2019CompletedRelative Change From Baseline in Whole Liver Fat at Day 15 as Assessed by Magnetic Resonance Imaging (MRI) - Proton Density Fat Fraction (PDFF)THR-β agonistsVK2809Primary hypercholesterolemia and MAFLDPhase IINCT029271842016-2019CompletedIn participants with NAFLD, ervogastat 50 and 300 mg q12h administered for 14 days resulted in robust dose-dependent reductions in whole liver fat assessed by MRI-PDFF (primary end point). Relative changes from baseline of –24.3% (80% CI, –31.3 to –16.7) for ervogastat 50 mg q12h and –33.9% (80% CI, –39.8 to –27.5) for ervogastat 300 mg q12h versus placebo were observed.Resmetirom(MGL-3196, FDA approved)MASHPhase IIINCT039004292019-2028On-going-MAFLDPhase IIINCT041974792019-2023CompletedResmetirom was safe and well tolerated. TEAEs occurred in 86.5% (open-label 100 mg resmetirom), 86.1% (100 mg resmetirom), 88.4% (80 mg resmetirom) and 81.8% (placebo) of patients. TEAEs in excess of placebo included diarrhea and nausea at the initiation of treatment. Key secondary end points included least square means difference from placebo at 80 mg, 100 mg resmetirom: LDL-C (−11.1%, −12.6%), apoB (−15.6%, −18.0%), triglycerides (−15.4%, −20.4%), 16-week hepatic fat (−34.9%, −38.6%), (P < 0.0001) and liver stiffness (−1.02, −1.70) and 52-week hepatic fat (−28.8, −33.9). Notes: Data source: clinicaltrials.gov. This table includes Phase I–III trials of drug development candidates for MAFLD/MASH with publicly available status or results as of October 2025. Trials were selected based on the availability of key outcome data and relevance to the therapeutic strategies discussed in this review. Table 1Representative Clinical Trials of Drug Development Candidates for MAFLD/MASH Included in This ReviewTarget/Drug ClassDrugPopulation/PatientsPhases of Clinical TrialsNCT Number (Reference)Trial PeriodCurrent StatusKey Findings/ConclusionPPAR agonistsLanifibranor (IVA-337)MASHPhase IINCT030080702017-2020CompletedThe percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher among those who received the 1200-mg dose, but not among those who received the 800-mg dose, of lanifibranor than among those who received placebo (1200-mg dose vs placebo, 55% vs 33%, P = 0.007; 800-mg dose vs placebo, 48% vs 33%, P = 0.07).T2DM and MAFLDPhase IINCT034590792018–2023CompletedLanifibranor significantly lowered IHTG compared to placebo (full analysis set [FAS] −44% vs −12%, respectively; least squares mean difference −31%, 95% CI −51 to −12%; in completers −50% vs −16%; both p <0.01).MASHPhase IIINCT048497282021-2026Ongoing-FGF19 analoguesAldafermin (NGM282)MASHPhase IINCT024431162015-2020CompletedAt week 24, the aldafermin group had a significant reduction in absolute liver fat content (reduction of 7.7%) compared with placebo (reduction of 2.7%; difference, reduction of 5.0%; 95% confidence interval, reduction of 8.0%-1.9%; P =0.002).FGF1R agonistsFazpilodemab (BFKB8488A)MAFLD and T2MDPhase INCT030605382017-2019CompletedBFKB8488A exhibited nonlinear pharmacokinetics, with greater than dose-proportional increases in exposure. The treatment-emergent antidrug antibody incidence was 22.7%.FGF21 analoguesPegozaferminMASHPhase IINCT049294832021-2024CompletedThe percentage of patients who met the criteria for NASH resolution was 2% in the placebo group, 37% in the 15-mg pegozafermin group (difference vs placebo, 35 percentage points; 95% CI, 10 to 59), 23% in the 30-mg pegozafermin group (difference, 21 percentage points; 95% CI, 9 to 33), and 26% in the 44-mg pegozafermin group (difference, 24 percentage points; 95% CI, 10 to 37).PegbelferminMASHPhase IINCT024133722015-2017CompletedThere is a significant decrease in absolute hepatic fat fraction in the group receiving 10 mg pegbelfermin daily (−6·8% vs −1·3%; p=0·0004) and in the group receiving 20 mg pegbelfermin weekly (−5·2% vs −1·3%; p=0·008) compared with the placebo group.Efruxifermin (EFX)MASHPhase IIINCT062157162023-2032Ongoing-SCD1 inhibitorsAramchol free acidMASHPhase IIINCT041043212019-2027SuspendedInterim analysis results from the open-label part of the study. The double blind portion of the study will be resumed once the study will continue.ASK1 inhibitorsSelonsertib (GS-4997)MASHPhase IIINCT030530502017-2019TerminatedThis study was terminated early due to lack of efficacy based on the results of the Week 48 analysis as prespecified in the clinical study protocol.MASHPhase IIINCT030530632017-2019TerminatedThis study was terminated early due to lack of efficacy based on the results of the Week 48 analysis as prespecified in the clinical study protocol.FASN inhibitorsDenifanstat (TVB-2640)MASHPhase IINCT039382462019-2021CompletedLiver fat increased in the placebo cohort by 4.5% relative to baseline; in contrast TVB-2640 reduced liver fat by 9.6% in the 25-mg cohort (n = 30; least squares mean: −15.5%; 95% confidence interval, −31.3 to −0.23; P =0.053), and 28.1% in the 50-mg cohort (n = 28; least squares mean: −28.0%; 95% confidence interval, −44.5 to −11.6; P =0.001).MPC inhibitorsMSDC-0602KMASHPhase IINCT027844442016-2019CompletedThe primary endpoint was reached in 29.7%, 29.8%, 32.9% and 39.5% of patients in the placebo, 62.5 mg, 125 mg and 250 mg dose arms, respectively, with adjusted odds ratios relative to placebo of 0.89 (95% CI 0.44–1.81), 1.22 (95% CI 0.60–2.48), and 1.64 (95% CI 0.83–3.27). The 2 highest doses of MSDC-0602K led to significant reductions in glucose, glycated hemoglobin, insulin, liver enzymes and NAS compared to placebo. AMPK activatorsPXL770MAFLDPhase IINCT037638772019-2020CompletedThe mean relative change from baseline in liver fat content at week 12 was −1·1% in the placebo group, −1·0% in the 250 mg once daily group (mean difference versus placebo 0·1% [95% CI −15·4 to 15·7], p=0·99), −14·3% in the 250 mg twice daily group (−13·1% [−28·1 to 1·8], p=0·084), and −14·7% in the 500 mg once daily group (−13·5% [−28·5 to 1·4], p=0·076).Oltipraz(RP 35972)MAFLD except liver cirrhosisPhase IIINCT041427492019-2022CompletedNo Study Results Posted on ClinicalTrials.gov for this StudyCCR2/5 inhibitorsCenicrivirocMASHPhase IIINCT030287402017-2021TerminatedThis study was terminated early due to lack of efficacy based on the results of the planned interim analysis of Part 1 data.AOC3 inhibitorBI 1467335MASHPhase IINCT031667352017-2019CompletedMean AOC3 activities relative to baseline at Week 12: 90.4% (placebo; n = 32), 26.5% (1 mg; n = 16), 10.4% (3 mg; n = 16), 5.0% (6 mg; n = 16), 3.3% (10 mg; n = 32). These changes indicated that BI 1467335 dose-dependently inhibited AOC3 activity; ≥3 mg doses achieved >80% inhibition (< 20% activity) at Week 4.Pan-PDE inhibitorZSP1601MASHPhase I/IINCT041401232020-2021CompletedThe primary outcomes were the safety and tolerability of ZSP1601. A total of 27 (27/36, 75%) patients experienced at least one treatment-emergent adverse event (TEAE). Most TEAEs were mild to moderate. There was no Serious Adverse Event. Diarrhea, transiently elevated creatinine and adaptive headache were frequently reported adverse drug reaction.FXR agonistsTropifexor (LJN452)MASHPhase IINCT028551642016-2020TerminatedDecreases from baseline in ALT and HFF were greater with tropifexor versus placebo at week 12, with a relative decrease in least squares mean from baseline observed with all tropifexor doses for ALT (tropifexor 10–90-μg dose groups ranged from −10.7 to −16.5 U l−1 versus placebo (−7.8 U l−1) and tropifexor 140- and 200-μg groups were −18.0 U l−1 and −23.0 U l−1, respectively, versus placebo (−8.3 U l−1)) and % HFF (tropifexor 10–90-μg dose groups ranged from −7.48% to −15.04% versus placebo (−6.19%) and tropifexor 140- and 200-μg groups were −19.07% and −39.41%, respectively, versus placebo (−10.77%)). Decreases in ALT and HFF were sustained up to week 48; however, similar trends in AST with tropifexor at week 12 were not observed. As with other FXR agonists, dose-related pruritus was frequently observed.EDP-305MASHPhase IINCT043780102020-2021TerminatedEnanta Pharmaceuticals, Inc. made the strategic decision to discontinue the ARGON-2 study to prioritize combination treatment approaches. This decision was not based on safety concerns.GLP1R/GCGR/GIPR agonistsEfinopegdutide (MK-6024)MAFLDPhase IINCT049449922021-2022CompletedThe least squares (LS) mean relative reduction from baseline in LFC at Week 24 was significantly (p <0.001) greater with efinopegdutide (72.7% [90% CI 66.8–78.7]) than with semaglutide (42.3% [90% CI 36.5–48.1]). Both treatment groups had an LS mean percent reduction from baseline in body weight at Week 24 (efinopegdutide 8.5% vs semaglutide 7.1%; p = 0.085).HSD17B13 inhibitorsARO-HSD (GSK4532990)MASHPhase IINCT055833442023-2026Ongoing-INI-822MASHPhase INCT059455372023-2025Ongoing-DGAT1/2 inhibitorsErvogastat (PF-06865571)MAFLDPhase INCT035135882018-2019CompletedRelative Change From Baseline in Whole Liver Fat at Day 15 as Assessed by Magnetic Resonance Imaging (MRI) - Proton Density Fat Fraction (PDFF)THR-β agonistsVK2809Primary hypercholesterolemia and MAFLDPhase IINCT029271842016-2019CompletedIn participants with NAFLD, ervogastat 50 and 300 mg q12h administered for 14 days resulted in robust dose-dependent reductions in whole liver fat assessed by MRI-PDFF (primary end point). Relative changes from baseline of –24.3% (80% CI, –31.3 to –16.7) for ervogastat 50 mg q12h and –33.9% (80% CI, –39.8 to –27.5) for ervogastat 300 mg q12h versus placebo were observed.Resmetirom(MGL-3196, FDA approved)MASHPhase IIINCT039004292019-2028On-going-MAFLDPhase IIINCT041974792019-2023CompletedResmetirom was safe and well tolerated. TEAEs occurred in 86.5% (open-label 100 mg resmetirom), 86.1% (100 mg resmetirom), 88.4% (80 mg resmetirom) and 81.8% (placebo) of patients. TEAEs in excess of placebo included diarrhea and nausea at the initiation of treatment. Key secondary end points included least square means difference from placebo at 80 mg, 100 mg resmetirom: LDL-C (−11.1%, −12.6%), apoB (−15.6%, −18.0%), triglycerides (−15.4%, −20.4%), 16-week hepatic fat (−34.9%, −38.6%), (P < 0.0001) and liver stiffness (−1.02, −1.70) and 52-week hepatic fat (−28.8, −33.9). Notes: Data source: clinicaltrials.gov. This table includes Phase I–III trials of drug development candidates for MAFLD/MASH with publicly available status or results as of October 2025. Trials were selected based on the availability of key outcome data and relevance to the therapeutic strategies discussed in this review. Representative Clinical Trials of Drug Development Candidates for MAFLD/MASH Included in This Review Notes: Data source: clinicaltrials.gov. This table includes Phase I–III trials of drug development candidates for MAFLD/MASH with publicly available status or results as of October 2025. Trials were selected based on the availability of key outcome data and relevance to the therapeutic strategies discussed in this review. Given the lack of targeted therapies for MAFLD, European practice guidelines recommend prioritizing the treatment of closely related comorbidities, such as T2DM and cardiovascular diseases, which leads to the adoption of certain existing medications in specific patient subgroups.15 For instance, statins for non-alcoholic steatohepatitis (NASH) patients with dyslipidemia to reduce cardiovascular risk, pioglitazone for biopsy-confirmed NASH patients, and vitamin E for short-term management of specific non-cirrhotic NAFLD patients.16 These efforts represent repurposing existing drugs based on overlapping mechanisms of action with key pathological pathways of the disease. Drug repurposing refers to the process of identifying new indications for existing drugs to explore their potential therapeutic value.17 This strategy could reduce the time, cost, and risks of de novo drug development by leveraging established safety data and drug pleiotropy.18–20 Classic successes include sildenafil (Viagra)21 and thalidomide.22 During the COVID-19 pandemic, repurposing proved vital, with remdesivir23 and dexamethasone23 rapidly authorized based on existing clinical data. During the Coronavirus disease 2019 (COVID‑19) pandemic, drug repurposing shifted rapidly from concept to urgent practice, with several existing drugs evaluated for anti‑SARS‑CoV‑2 potential. Remdesivir, originally an Ebola antiviral, showed in vitro inhibition of SARS‑CoV‑2 replication. Interim results from the ACTT‑1 trial in 2020 indicated shortened recovery time in hospitalized patients, leading the US FDA to grant Emergency Use Authorization in May 2020—making it the first approved COVID‑19 therapy. Dexamethasone, a widely used anti‑inflammatory corticosteroid, was assessed in the RECOVERY trial launched in March 2020. Its June 2020 interim results showed about one‑third reduction in mortality for patients on invasive ventilation and one‑fifth for those on oxygen; the WHO updated its guidelines within weeks to recommend it for severe and critical cases. These cases demonstrate the potential and significance of drug repurposing in multiple therapeutic fields. This offers a unique therapeutic potential for intervening in the complex, multisystem pathophysiological processes underlying MAFLD. In recent years, technological advances have enabled drug repurposing to move beyond chance observation toward systematic, mechanism-driven discovery.24,25 Modern strategies integrate multiple methodologies: clinical observation of unintended beneficial effects in real-world settings (real-world evidence);26 computational strategies to match signatures;27 and experimental strategies to realistic disease models.28 By aligning candidate compounds with the molecular mechanisms of diseases such as MAFLD and its metabolic comorbidities, these integrated, technology-enhanced strategies promise to transform drug development, accelerating the translation of existing therapies into new clinical uses. As a preliminary investigation for this review, we conducted a literature search in PubMed and clinical trial registries up to October 2025 using terms related to MAFLD. Of the 826 studies identified, over 100 focused on statins for MAFLD/MASH and its complications. Repurposed drugs generally target MAFLD comorbidities or key pathological pathways (eg, metabolic dysregulation, inflammation). For example, PPAR agonists such as elafibranor can enhance insulin sensitivity and have currently entered the pivotal Phase III clinical trial stage.29 In addition, FXR agonists such as ursodeoxycholic acid have shown significant antifibrotic effects by regulating bile acid homeostasis.30 Ursodeoxycholic acid was initially developed as a bile acid analog and has now been confirmed to have significant efficacy in alleviating liver fibrosis in MASH patients.31 The antiviral drug cenicriviroc and the immunomodulator belapectin have shown potential in alleviating hepatitis and liver fibrosis.32 Table 2 shows the five most frequently reported repurposing drugs in MAFLD. These attempts indicate that drug repurposing could open up new avenues for MAFLD treatment and reduce the development risk associated with traditional de novo drug development.Table 2Representative Drug Candidates Repurposed for MAFLD/MASH Included in This ReviewDrug NameGenetic CorrelationsPrimary TargetOriginal IndicationNCT numberClinical PhaseCurrent StatusTrial PeriodKey Findings/ConclusionSemaglutidePNPLA3 rs738409/MBOAT7 rs641738GLP-1R agonistT2DM/ObesityNCT04822181Phase IIIOngoing2021-2029Obeticholic AcidPNPLA3 rs738409/ HSD17B13 rs72613567FXR agonistPrimary biliary cholangitisNCT02548351Phase IIITerminated2015-2023The FDA issued a CRL in response to Intercept’s NDA for OCA for the treatment of NASH. Sponsor decided to terminate 747–303 before the planned completion date.CenicrivirocPNPLA3 rs738409/TM6SF2 rs58542926CCR2/5 inhibitorHIV infectionNCT03028740Phase IIITerminated2017-2021This study was terminated early due to lack of efficacy based on the results of the planned interim analysis of Part 1 data.ElafibranorPNPLA3/TM6SF2/HSD17B13 variantsPPARα/δ agonistPrimary biliary cholangitisNCT02704403Phase IIITerminated2016-2020Study did not meet the predefined primary surrogate efficacy endpoint, no safety issues identifiedDapagliflozinPNPLA3SGLT2 inhibitorT2DM/CKDNCT03723252Phase IIICompleted2019-2024MASH improvement without worsening of fibrosis was reported in 53% (41/78) of participants in the dapagliflozin group and 30% (23/76) in the placebo group (risk ratio 1.73 (95% confidence interval (CI) 1.16 to 2.58); P=0.006). Notes: Data source: clinicaltrials.gov. This table summarizes representative drugs that have been investigated for repurposing in MAFLD/MASH, as identified from the literature and clinical trial registries. Candidates were selected based on the availability of clinical or preclinical evidence supporting their repurposing potential and relevance to the therapeutic strategies discussed in this review. Table 2Representative Drug Candidates Repurposed for MAFLD/MASH Included in This ReviewDrug NameGenetic CorrelationsPrimary TargetOriginal IndicationNCT numberClinical PhaseCurrent StatusTrial PeriodKey Findings/ConclusionSemaglutidePNPLA3 rs738409/MBOAT7 rs641738GLP-1R agonistT2DM/ObesityNCT04822181Phase IIIOngoing2021-2029Obeticholic AcidPNPLA3 rs738409/ HSD17B13 rs72613567FXR agonistPrimary biliary cholangitisNCT02548351Phase IIITerminated2015-2023The FDA issued a CRL in response to Intercept’s NDA for OCA for the treatment of NASH. Sponsor decided to terminate 747–303 before the planned completion date.CenicrivirocPNPLA3 rs738409/TM6SF2 rs58542926CCR2/5 inhibitorHIV infectionNCT03028740Phase IIITerminated2017-2021This study was terminated early due to lack of efficacy based on the results of the planned interim analysis of Part 1 data.ElafibranorPNPLA3/TM6SF2/HSD17B13 variantsPPARα/δ agonistPrimary biliary cholangitisNCT02704403Phase IIITerminated2016-2020Study did not meet the predefined primary surrogate efficacy endpoint, no safety issues identifiedDapagliflozinPNPLA3SGLT2 inhibitorT2DM/CKDNCT03723252Phase IIICompleted2019-2024MASH improvement without worsening of fibrosis was reported in 53% (41/78) of participants in the dapagliflozin group and 30% (23/76) in the placebo group (risk ratio 1.73 (95% confidence interval (CI) 1.16 to 2.58); P=0.006). Notes: Data source: clinicaltrials.gov. This table summarizes representative drugs that have been investigated for repurposing in MAFLD/MASH, as identified from the literature and clinical trial registries. Candidates were selected based on the availability of clinical or preclinical evidence supporting their repurposing potential and relevance to the therapeutic strategies discussed in this review. Representative Drug Candidates Repurposed for MAFLD/MASH Included in This Review Notes: Data source: clinicaltrials.gov. This table summarizes representative drugs that have been investigated for repurposing in MAFLD/MASH, as identified from the literature and clinical trial registries. Candidates were selected based on the availability of clinical or preclinical evidence supporting their repurposing potential and relevance to the therapeutic strategies discussed in this review. However, translating these promising candidates into clinical practice faces substantial challenges. Patient heterogeneity in metabolic background, fibrosis stage, and genetic susceptibility complicates the identification of patient subgroups most likely to benefit from specific repurposed agents.33 The lack of validated, non-invasive biomarkers for patient stratification and treatment response monitoring remains a critical bottleneck.34 Furthermore, inconsistency in histologic endpoint selection across trials has complicated cross-study comparisons and hindered regulatory decision-making.35 These obstacles collectively underscore the need for more rigorous, mechanism-informed repurposing strategies. Therefore, this review aims to analyze current research on drug repurposing for MAFLD by synthesizing key strategies and recent findings, so as to inform future therapeutic development. Clinical Strategies Real-World Evidence Real-world evidence, including clinical trials and EHRs, represents a cornerstone in drug repurposing for MAFLD. Clinical trials confirmed therapeutic potentials identified through observational data.36 For example, the clinical trial NCT04944992 demonstrated that semaglutide, a GLP-1 receptor agonist originally approved for T2DM, significantly reduces hepatic lipid accumulation in MAFLD patients.37 This trial exemplifies how repurposed agents like semaglutide, which exhibit metabolic-regulatory off-target effects, can be validated for MAFLD through clinical evidence, mirroring the paradigm established by the repurposing of sildenafil for erectile dysfunction. Other clinical trials, such as those evaluating the CCR2/CCR5 inhibitor cenicriviroc38 and the galectin-3 antagonist belapectin,39 have also shown promising results in improving fibrosis and reducing liver-related events. Concurrently, large-scale EHRs provide a robust framework for identifying repurposed therapeutics in MAFLD.40 Evidence from T2DM and cardiovascular disease has demonstrated that EHR-driven interventions can enhance screening and treatment adherence in those populations,41–43 but whether these findings translate directly to MAFLD requires further investigation. This strategy could enable data-informed therapeutic optimization, provided that challenges such as data heterogeneity, missing variables, and confounding by indication are adequately addressed. A multidisciplinary approach integrating clinical registries, computational modeling, and multi-omics profiling may accelerate discovery,44 although the optimal integration strategy and validation standards remain to be established. Platform trials leveraging longitudinal EHRs, non-invasive imaging biomarkers, and molecular profiling could facilitate repurposed agent validation,45–47 yet such trials are still in early phases and their feasibility in MAFLD needs prospective evaluation. If rigorously validated algorithms and collaborative frameworks are successfully implemented, these approaches might uncover novel therapies and ultimately improve outcomes for metabolic liver disease patients.48 Side Effects Reporting A key strategy in drug repurposing entails leveraging adverse drug reactions (ADRs) to uncover therapeutic potentials in unrelated diseases.49,50 Despite ADRs posing challenges in drug development, they provide invaluable phenotypic data. The SIDER database integrates drug—ADR relationships, frequency metrics, and indications to refine mechanistic insights and minimize false positives in side-effect analysis.51 Researchers employ systematic approaches—including the Unified Medical Language System (UMLS) ontology,52 natural language processing models,53 and machine learning methods, which have revealed strong side effect associations across numerous approved drugs. Regulatory databases, such as the FDA Adverse Event Reporting System (FAERS), the Medicines and Healthcare products Regulatory Agency (MHRA), the Eudra Vigilance data analysis system (EVDAS), and the World Health Organization (WHO) VigiBase, offer large-scale population data for such analyses of repurposing via beneficial side effects includes sildenafil, initially developed for hypertension but repurposed for erectile dysfunction following its vasodilatory effects.54,55 Semaglutide, a GLP-1 receptor agonist approved for T2DM, demonstrated cardiovascular benefits,56 prompting investigations into its role in peripheral artery disease.57 Minoxidil, a calcium channel blocker for hypertension, was repurposed for alopecia after its hair growth-promoting effects were identified.58 Applying this paradigm to MAFLD remains hypothetical. Systematic mining of side-effect signals might identify drugs with metabolic-regulatory, anti-inflammatory, or antifibrotic off-target effects, such as unexpected improvements in hepatic lipid accumulation. While regulatory databases enable hypothesis generation and candidate prioritization, their limitations—underreporting, reporting bias, confounding, and the fact that association does not prove causation—must be acknowledged. Any candidates identified require preclinical and clinical validation. Mechanistic investigation of observed side effects may offer biological insights into MAFLD, but generalizability from pharmacovigilance data to this disease needs careful evaluation. Computational Strategies Genome-Wide Association Studies Genome-wide association studies (GWAS) have revolutionized our understanding of the genetic architecture of MAFLD.59–62 Robust associations exist between disease progression and polymorphisms in genes regulating hepatic lipid metabolism, including patatin-like phospholipase domain-containing proteins 3 (PNPLA3), transmembrane 6 superfamily member 2 (TM6SF2), membrane‑bound O-acyltransferase domain containing 7 (MBOAT7), Glucokinase regulator (GCKR), hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), mitochondrial amidoxime–reducing component 1 (MARC1), Apolipoprotein E (APOE), and glycerol‐3‐phosphate acyltransferases, mitochondrial (GPAM).59,63,64 Among these genes, variants in PNPLA3 and TM6SF2 exhibit particularly strong correlations with susceptibility to MASLD-related liver injury.63 The PNPLA3 I148M variant (rs738409) has been consistently linked to increased hepatic fat accumulation and elevated liver-related mortality, particularly in Asian populations.65,66 Similarly, TM6SF2 loss-of-function variants impair very-low-density lipoprotein (VLDL) secretion, promoting intrahepatic lipid retention and predisposing individuals to MASH and fibrosis.67 The MBOAT7 gene encodes LPIAT1. The rs641738 variant reduces its expression and has emerged as a key genetic target in NAFLD. This polymorphism amplifies hepatic steatosis, insulin resistance, inflammation and fibrosis, markedly increasing the risk of MASH and hepatocellular carcinoma. Its effect is independent of obesity or alcohol, yet it synergizes with both to accelerate disease. Low MBOAT7 expression correlates with elevated serum alanine aminotransferase (ALT) and worsening histological scores. Animal studies show that restoring MBOAT7 function reverses steatosis and fibrosis, highlighting its therapeutic potential; targeting this variant can correct lipid dysregulation, lessen liver injury and lower oncogenic risk.67,68 HSD17B13 has emerged as a disease modifier. The rs62305723 and rs72613567 variants blunt retinol dehydrogenase activity, attenuate hepatic inflammation and ballooning in MAFLD, yet curtail retinoic acid, erode antioxidant defenses and sensitize hepatocytes to lipotoxicity, an “anti-inflammatory but pro-vulnerability” paradox. Carriers enjoy lower ALT and reduced NASH risk, yet extreme obesity or alcohol can still precipitate rapid injury. Thus, HSD17B13 is a double-edged sword: partial inhibition cools inflammation, but complete blockade may strip cytoprotection, demanding carefully titrated, context-aware intervention.67 Elevated apolipoprotein B (ApoB) levels, a MAFLD hallmark, dyslipidemia and cardiovascular complications, underscoring metabolic-hepatic crosstalk.69 Defining these genetic risk factors has informed therapeutic strategies, including GWAS-guided drug repurposing. Targeting disrupted pathways—particularly those involving PNPLA3, TM6SF2, and HSD17B13—holds promise for mitigating steatosis, inflammation, and fibrosis in MASH.70 While GWAS offers opportunities for repurposing, proposed agents require conclusive validation.62,71,72 Currently, research on multi-target drug combinations remains scarce. Looking forward, GWAS-based discovery could gain momentum by following a “gene–mechanism–intervention” paradigm. Integration of trans-ancestry GWAS, quantitative trait locus (xQTL), and single-cell multi-omics combined with algorithms such as pgBoost and OPERA may help map non-coding signals to causal genes and druggable targets, generating a prioritized list for repurposing. Concurrently, AI-driven platforms, CRISPRi phenotypic screening, and biobank-derived real-world data could validate safety and synergy of candidate combinations. Whether these integrated approaches will successfully translate “genetically stratified” combination strategies into clinical practice remains to be confirmed, but they offer a potential pathway toward more precise and cost-effective individualized treatment for MAFLD and MASH. Association by Chemical Structure The chemical structure of a drug is a fundamental determinant of its biological activity.73 By comparing chemical profiles to identify structural similarities that imply shared biological activities, researchers can uncover new therapeutic applications for existing drugs.17 This approach exemplifies a core strategy in drug repurposing. For instance, Keiser et al employed a similarity ensemble method to assess 2D structural similarity between drugs and target ligand sets, successfully identifying novel drug–target associations.74 In the context of MAFLD, platforms like NAFLDkb75 and DrugRepo76 leverage knowledge graph-based frameworks to facilitate repurposing. These platforms integrate chemical structure search and drug similarity screening functions, enabling the identification of compounds with structures analogous to approved MAFLD therapeutics. For example, NAFLDkb has identified three repurposed drug candidates and 137 lead-like compounds for MAFLD, demonstrating its potential to accelerate drug development.75 Additionally, computational frameworks such as Drug Repurposing through Exploring Associations using multi-layer random walk (DREAMwalk),77 which incorporates semantic information-guided teleportation in random walk algorithms—predict drug–disease associations for MAFLD. Another network-based approach combines in vitro steatosis models with a computational platform built from genomic data of diseased liver biopsies and compound-treated cell lines.78 This framework evaluates compounds in silico and validates them in vitro, enabling high-throughput screening and prioritization of candidates. However, chemical similarity-based approaches have inherent limitations. The inaccuracy of structural annotations and physiological effects that extend beyond structural relationships may compromise their effectiveness. For instance, active metabolites with modified structures—rather than the parent drugs—may drive therapeutic effects, yet this complexity cannot be captured solely through structural similarity. To address these challenges, a more productive strategy may lie in multidimensional integration by verifying target physiological effects via multi-omics functional annotation, incorporating AI-driven phenotypic screening based on hepatic lipid accumulation rather than structural similarity, and tracking active metabolite dynamics through trajectory modeling. Such integration could help identify repurposing candidates that transcend structural constraints, although the practical implementation of these combined approaches faces technical hurdles, including data harmonization across platforms and the complexity of metabolite modeling, which require further methodological development. Association by Transcriptomic Profiling Tanscriptomics—uncover disease-associated genes and pathways by profiling RNA expression, augmenting mechanistic understanding of MAFLD and enabling computational drug–disease signature matching for repurposing.79 Preclinical transcriptomic analyses have identified drug metabolism genes in MASH/MAFLD and non-invasive biomarkers such as growth differentiation factor 3 (GDF3), which correlates with hepatic inflammation and fibrosis severity, while constructing gene signatures for risk stratification of disease progression to MASH or hepatocellular carcinoma.80 Critically, drug-repositioning pipelines leveraging these data have identified candidates such as AZD3355 (Lesogaberan), a GABA-B receptor agonist originally developed for esophageal reflux, which exhibits hepatoprotective effects by reducing hepatic triglyceride accumulation and inhibiting pro-fibrotic transforming growth factor-β (TGF-β) signaling in MASH models.81 Transcriptome-based screens have also yielded novel leads targeting MAFLD’s metabolic core. Cheng Zhang et al identified 10 small-molecule pyruvate kinase liver and RBC (PKLR) inhibitors, with two suppressing PKLR-mediated glycolysis to reduce hepatic lipid synthesis in vitro and alleviate steatosis in high-fat diet rat models—key pathological features of MAFLD—without off-target effects82 large-scale transcriptomic databases further accelerate discovery: Hua Ye applied weighted gene co-expression network analysis to 11 MAFLD tissue datasets, identifying hub genes involved in lipid droplet formation and mitochondrial dysfunction—hallmarks of MAFLD pathophysiology—and suggesting repurposed candidates via Connectivity Map analysis.83 The PharmOmics platform developed by Yen-Wei Chen et al exemplifies this approach, integrating transcriptomic data from GEO, ArrayExpress, TG-GATEs, and DrugMatrix across human, mouse, and rat tissues.84 Using multi-species gene-expression profiles as molecular markers, this tool predicted drugs that normalize MAFLD-associated gene networks, such as PPAR agonists that restore lipid homeostasis and reduce hepatic inflammation, validating two candidates in murine NAFLD models. These findings demonstrate the utility of transcriptomic profiling for candidate identification. However, whether such preclinical predictions reliably translate to human MAFLD—characterized by dysregulated lipid metabolism, endoplasmic reticulum stress, and inflammatory signaling—requires further validation in clinical settings. The approach holds promise for de-risking repurposing pipelines, but its generalizability and predictive accuracy remain to be established across diverse patient populations. Phenome-Wide Association Studies Phenotype-driven drug repositioning identifies new therapeutic indications by analyzing drug-induced cellular or organismal phenotypic changes, distinguishing itself from target-based approaches by focusing on disease-relevant phenotype improvement.85 Pathogenesis of MAFLD involves complex interplay between lipid droplet accumulation, mitochondrial dysfunction, and inflammatory signaling—heterogeneous phenotypes that traditional target-based methods often overlook. Thus, this strategy of phenotype-driven drug repositioning is particularly valuable for MAFLD. Weng et al adopted a phenotype-driven approach, using high-content imaging to screen for factors that modulate a core pathological phenotype in MAFLD—lipid accumulation. This strategy identified TRIM56, an E3 ubiquitin ligase with lipid-lowering effects in MAFLD models.86 Mechanistically, TRIM56 acts by ubiquitinating fatty acid synthase (FASN), a key enzyme in de novo lipogenesis, thereby inhibiting hepatic fat synthesis and slowing disease progression. Guided by this phenotype-linked mechanism, they developed FASstatin, a novel FASN inhibitor. In vitro, it suppresses intracellular lipid deposition by blocking FASN enzymatic activity and protein expression; in vivo, it safely reduces hepatic lipid accumulation, alleviating steatosis and inflammatory fibrosis in mouse models of MAFLD and MASH. Wang et al87 developed MitoReID, an AI-driven platform leveraging mitochondrial phenotypic profiling for drug screening. By analyzing dynamic mitochondrial changes induced by compounds, MitoReID predicts drug mechanisms and targets—particularly relevant to MAFLD, where mitochondrial dysfunction drives lipid dysmetabolism and endoplasmic reticulum stress. This technology has been used to identify targets of traditional Chinese medicine components that normalize mitochondrial morphology and bioenergetics in MAFLD cell models. These phenotype-driven approaches leverage MAFLD’s heterogeneous cellular phenotypes, such as lipid droplet accumulation and mitochondrial dysfunction, and may accelerate repurposing of both small molecules and natural products. The integration of multi-omics data with cellular phenotyping could offer a path to personalized MAFLD therapy, particularly for patients with TM6SF2 or PNPLA3 genetic variants, who show distinct lipid droplet and mitochondrial phenotypes. However, whether these phenotypic signatures could translate into differential drug responses in genotype-stratified patients remains to be determined, and the clinical utility of such personalized repurposing strategies requires prospective evaluation. Experimental Strategies Experimental Approaches Experimental approaches are pivotal for MAFLD drug repurposing, capturing its heterogeneous phenotypes—lipid dysmetabolism, mitochondrial dysfunction, and inflammation—beyond traditional single-target limitations. These methods integrate genetic risk profiles with functional modeling to prioritize phenotype-driven therapeutic strategies, addressing a critical gap in translating omics discoveries into clinical applications. Induced pluripotent stem cells (iPSCs)-derived hepatocyte-like cells (HLCs) and 3D liver organoids offer physiologically relevant models for MAFLD.88 2D-differentiated HLCs recapitulate key features. Patient-derived lines carrying PNPLA3 I148M variants show 47% higher triglyceride accumulation and dysregulated SREBP-1c/lipogenic gene networks, mirroring clinical steatosis.89 Gene-editing via Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9 (CRISPR-Cas9) further enables targeted modulation—for example, knocking in TM6SF2 loss-of-function variants to induce 32% increased lipid droplet aggregation, mimicking human genetic susceptibility.90 3D organoids, formed via self-assembly of iPSC-HLCs with mesenchymal stromal cells, exhibit zonate metabolic activity (eg, periportal CYP3A4 expression) and biliary-like structures, critical for modeling cholestatic fibrosis. Zebrafish larvae leverage transparent embryogenesis and 82% gene conservation with humans for in vivo phenotyping. CRISPR screens targeting MAFLD-associated genes have identified klf12 as a regulator of steatosis. Morpholino knockdown has been shown to cause a 60% increase in liver fat accumulation, thereby recapitulating the effects of the human KLF12 polymorphism.91 High-content chemical screens using Nile red staining have validated repurposing candidates. Simvastatin reduces liver triglycerides by 44% via PPARγ activation. And this finding was translated to a phase II trial where the drug improved steatosis in 58% of MAFLD patients.92 Zebrafish also enable real-time imaging of fibrosis using transgenic lines expressing GFP in hepatic stellate cells, allowing quantification of TGF-β1-induced matrix deposition. iPSC and zebrafish models could accelerate MAFLD drug discovery by integrating genetic risk profiling with functional assays. Global consortia may consider formalizing cross-model validation frameworks to ensure compound efficacy across systems, as demonstrated for THR-β agonists. While technical limitations persist—iPSC-HLCs lacking stromal interactions and zebrafish requiring humanized enzymes—these platforms may support precision medicine by screening repurposing candidates tailored to patient genetics.93 Emerging AI-driven data fusion may help address current bottlenecks and facilitate progress toward mechanism-based, stratified repurposing. However, whether phenotypic readouts from these models could reliably predict clinical responses in MAFLD patients requires systematic evaluation, and the integration of AI-driven approaches into regulatory-acceptable validation pipelines remains to be established. Natural Products Natural products including traditional Chinese Medicine (TCM) serve as invaluable reservoirs of bioactive compounds for MAFLD drug repurposing, leveraging their polypharmacological properties and millennia of clinical validation. Modern analytical techniques have characterized over 2,000 TCM-derived molecules, many of which modulate key pathways like AMPK/SREBP-1 lipid signaling and NF-κB-mediated inflammation, offering distinct advantages over single-target synthetic drugs. Notably, bioactive compounds like alkaloids, flavonoids, and terpenoids—isolated from TCM herbs such as Salvia miltiorrhiza (Danshen, 丹参) and Artemisia annua (Qinghao, 青蒿)—directly address MAFLD’s complex pathogenesis, encompassing lipid dysmetabolism, inflammation, and fibrosis.94,95 Beyond individual TCM-derived molecules, TCM compounds further excel in MAFLD treatment through multi-target regulation. For instance, those with the effect of Qushihuayu (祛湿化瘀) exert hepatoprotective effects against steatosis and liver fibrosis by inhibiting MAPK pathway phosphorylation, promoting PPAR-γ and p-p65 translocation into the cell nucleus, and enhancing hematopoietic stem cell reprogramming.96 In contrast, TCM compounds with the effect of Jianpihuoxue (健脾活血) demonstrate hepatoprotective effects by targeting lipid accumulation, fibrosis, inflammation, and apoptosis.97 The polypharmacological nature of natural products aligns inherently with MAFLD’s heterogeneous pathology. Danshen, for example, exerts dual effects. Salvianolic acid A suppresses hepatic lipid accumulation by activating the AMPK/SREBP-1 axis, while tanshinones inhibit TNF-α-induced NF-κB signaling to reduce inflammation.95 This multi-target strategy is further exemplified by JiGuCao Capsule, which regulates the gut–liver axis by enhancing Akkermansia muciniphila abundance and activating PPARγ-CD36 pathways, addressing insulin resistance, steatosis, and fibrosis concurrently.98 Such holistic regulation contrasts with conventional drugs, reflecting TCM’s systemic therapeutic philosophy. TCM’s long-standing clinical experience in metabolic disorder management confers unique translational benefits. Natural products often exhibit favorable safety profiles. The herbal formula Yanggan Jieyu Granule showed no significant toxicity in postmenopausal MAFLD patients, with mild gastrointestinal symptoms as the primary adverse event. This low toxicity stems from evolutionary adaptation in traditional medical systems and reduced off-target effects relative to synthetic compounds. Additionally, repurposing existing TCM formulations offers substantial cost savings. While novel chemical entity development costs $1–2 billion and takes 10–15 years, TCM repurposing reduces costs by 60–70%.99 Synthetic biology—such as yeast-engineered production of artemisinin derivatives—further accelerates scalable manufacturing, overcoming historical bottlenecks in natural product supply. Natural products and TCM represent an underexplored area for MAFLD therapy, combining multi-target efficacy, clinical safety, and economic viability. As multi-omics integration and AI-driven screening advance, their polypharmacological potential—exemplified by Danshen’s dual anti-steatotic and antifibrotic activities—could help bridge traditional wisdom with precision medicine. However, several challenges remain. The active constituents of many TCM formulations are not fully characterized, quality control and standardization across batches pose significant hurdles, and the mechanistic basis of their polypharmacological effects is often incompletely understood. Moreover, most evidence currently derives from preclinical studies or small-scale clinical observations, and large-scale randomized controlled trials are needed to establish definitive efficacy in MAFLD. Whether these approaches can offer sustainable solutions for this complex metabolic disorder therefore requires further investigation. Implications for Future Research Drug repurposing for MAFLD with limited ongoing clinical translation necessitates solutions to interconnected challenges that hinder precise treatment, including fragmented multi-omics datasets, siloed electronic health records, and inadequate interpretation of associations between GWAS-identified susceptibility genes (eg, PNPLA3, TM6SF2) and clinical phenotypes. Further constraints arise from ambiguous diagnostic criteria for subtypes such as MASH. Technically, iPSC-derived organoids lack non-parenchymal cell crosstalk, and animal models poorly recapitulate human fibrosis, limiting translational accuracy. Industrially, expired patents diminish market incentives, rare subtypes offer low commercial value, and international regulatory discrepancies further impede progress. Addressing these barriers may require integrating GWAS and multi-omics data via federated learning, simulating gene–environment interactions using 3D organ chips, and combining policy incentives (eg, extended data exclusivity) with public–private partnerships. Such technological and institutional innovations could contribute to the development of personalized MAFLD therapies, provided that their feasibility, scalability and their actual impact on patient outcomes are rigorously evaluated in real-world settings. Conclusion This review has examined the challenges in developing novel MASLD therapeutics and evaluated drug repurposing as a complementary strategy. By synthesizing recent advancements in discovery and repurposing initiatives, we have highlighted how integrating real-world clinical data, computational methodologies, and experimental validation may address current research limitations. Our analysis indicates that, despite growing interest and investment in this area, the number of repurposed agents that have received regulatory approval for MASLD remains very limited. To date, only semaglutide, a GLP-1 receptor agonist originally developed for type 2 diabetes, has been approved as a repurposed therapy for MASLD, while most candidates continue to face substantial challenges in clinical translation. Key obstacles—including patient heterogeneity, absence of validated non-invasive biomarkers, inconsistent endpoint selection across trials, and limited mechanistic validation of drug–target interactions—continue to impede progress. Positioning repurposing as an analytical lens, this work suggests that its potential lies not only in accelerating therapeutic development but also in providing deeper insights into disease pathogenesis. However, realizing this potential will require sustained efforts in model system refinement, biomarker discovery, and harmonization of clinical trial design. Looking forward, integrating multi-omics profiling, AI-driven screening, and real-world evidence within mechanism-informed frameworks could facilitate more efficient repurposing strategies. Whether these integrated approaches will successfully translate into improved patient outcomes remains to be determined, but they represent a potential avenue for addressing the unmet needs of MASLD.